- Oops!Something went wrong.Please try again later.
Shares of Surmodics (NASDAQ:SRDX) rose 2.1% in pre-market trading after the company reported Q1 results.
Earnings per share fell 60.00% over the past year to $0.02, which beat the estimate of ($0.09).
Revenue of $22,297,000 declined by 1.41% year over year, which missed the estimate of $22,370,000.
Surmodics hasn't issued any earnings guidance for the time being.
Surmodics hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Feb 09, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/hqbfsddw
52-week high: $49.00
Company's 52-week low was at $22.06
Price action over last quarter: Up 28.33%
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. The company's mission is to improve the treatment and detection of disease by using our technology to provide solutions to a difficult medical device and diagnostic challenges. It has two reportable segments: Medical device unit and Vitro diagnostics unit. Surmodics derives most of its revenue from the Medical device segment.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.